Sarah Bennett
AstraZeneca is a pharmaceutical company with a large presence in the US, with primary locations in Gaithersburg, Maryland, and Wilmington, Delaware. The company developed a COVID-19 vaccine that has been the subject of controversy due to concerns about its possible association with blood clotting disorders. While the vaccine has been approved for use in Europe, it has not been approved by the US Food and Drug Administration (FDA). The FDA requires that at least half of the participants in vaccine trials have two months of follow-up data, and AstraZeneca has not yet submitted its vaccine for approval in the US. Experts initially predicted that AstraZeneca would be ready to apply for FDA approval in April, but the situation in Europe has caused delays.
| Characteristics | Values |
|---|---|
| AstraZeneca vaccine approval in the US | Not approved yet by the FDA |
| AstraZeneca locations in the US | Gaithersburg, MD; Wilmington, DE; Frederick (MD); Waltham (MA); Coppell (TX); Newark (DE); New York (NY); Durham (NC); Redwood City (CA); San Francisco (CA); Mount Vernon (IN); Shepherdsville (KY); Philadelphia (PA) |
| Concerns about AstraZeneca vaccine | Linked to blood clotting disorders and cardiovascular safety concerns |
Explore related products
$2.82 $24.95
What You'll Learn
- AstraZeneca's vaccine rollout in Europe was put on hold due to concerns about blood clotting
- AstraZeneca has not applied for approval in the US
- AstraZeneca has multiple locations in the US
- AstraZeneca's COVID-19 vaccine was found to be less safe than Pfizer's
- AstraZeneca's vaccine has not been approved by the FDA
AstraZeneca's vaccine rollout in Europe was put on hold due to concerns about blood clotting
AstraZeneca's vaccine rollout in Europe was put on hold in several countries, including Germany, Italy, France, Spain, Denmark, Norway, Cyprus, and Slovenia, due to concerns about blood clotting. The European Medicines Agency (EMA) reported that as of March 10, 2021, 30 cases of blood clotting had been identified among the nearly five million people vaccinated with the AstraZeneca vaccine in the European Economic Area.
In response to the concerns, AstraZeneca conducted a review of safety data from over 17 million vaccinated individuals in the United Kingdom and the European Union. The company's review found no evidence of an increased risk of blood clots, including pulmonary embolism, deep vein thrombosis, or thrombocytopenia, across different age groups, genders, batches, or countries. AstraZeneca acknowledged 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism but asserted that other licensed COVID-19 vaccines had reported similar rates of clotting.
Despite AstraZeneca's review, several countries decided to temporarily suspend the use of the vaccine. For instance, France's President Emmanuel Macron announced a 24-hour suspension, expressing hope to resume if the EMA provided a positive assessment. Similarly, Denmark and Norway halted the administration of the AstraZeneca vaccine after reporting isolated cases of bleeding, blood clots, and reduced platelet counts. Canada and Germany followed suit, suspending the vaccine's use for individuals under 55 and under 60, respectively.
The situation in Europe has had implications for the approval process in the United States. As of the time of the reports, the AstraZeneca vaccine had not yet been approved by the U.S. Food and Drug Administration (FDA). The FDA typically requires Phase III trial data with at least two months of follow-up for half of the participants, which AstraZeneca was still compiling. The concerns in Europe prompted experts to suggest that the FDA would likely consider the developments in Europe when evaluating the vaccine for approval in the United States.
Vaccinations in the US: Who Pays?
You may want to see also
Explore related products
AstraZeneca has not applied for approval in the US
AstraZeneca's COVID-19 vaccine has not yet been approved for use in the United States. The pharmaceutical company is yet to submit its vaccine for approval by the U.S. Food and Drug Administration (FDA). According to the FDA, the Emergency Use Authorization approval process cannot begin until AstraZeneca applies.
Experts suggest that AstraZeneca is several weeks away from being able to apply for FDA approval. Dr. William Moss, a vaccines expert from Johns Hopkins University, explained that the FDA requires that at least half of the participants in vaccine trials have two months of follow-up. This data then needs to be presented to the FDA for approval.
The rollout of the AstraZeneca vaccine has been paused in several European countries due to concerns about its possible association with blood clotting disorders. Dr. Bruce Walker, an immunology expert from Harvard Medical School, stated that the FDA would need to consider this situation when deciding whether to approve the vaccine.
Both Dr. Moss and Dr. Walker predict that AstraZeneca will be ready to apply for FDA approval in April. However, it is unclear when the vaccine will be approved for use in the United States, as the company has not yet submitted its application.
Garth Brooks Concert: Vaccination Requirements and Protocols
You may want to see also
Explore related products
AstraZeneca has multiple locations in the US
AstraZeneca's US operations are an integral part of its global business and healthcare initiatives. The company has a large presence in the US, with several key R&D, manufacturing, and commercial locations across the country.
The North American Commercial Business headquarters is located in Wilmington, Delaware, which is home to several integral business functions. The company also has two primary locations in North America: Gaithersburg, Maryland, and Wilmington, Delaware, where most of its US employees are based and work on global projects. The Gaithersburg, MD campus is one of three global research and development centers, along with Cambridge, UK, and Gothenburg, Sweden, dedicated to improving pipeline productivity and establishing AstraZeneca as a leader in biopharmaceutical innovation.
AstraZeneca's Gatehouse Park BioHub in Boston, Massachusetts, is another significant location, thriving with research companies and top scientists and experts. The BioHub was established as an R&D initiative to encourage life sciences discovery and the exchange of ideas. Additionally, AstraZeneca has sites in Frederick (MD), Waltham (MA), Coppell (TX), Newark (DE), New York (NY), Durham (NC), Redwood City (CA), San Francisco (CA), Mount Vernon (IN), and Shepherdsville (KY).
While AstraZeneca has a strong presence in the US with these multiple locations, it is important to note that as of April 2022, the company's COVID-19 vaccine had not yet been approved by the US Food and Drug Administration (FDA). The vaccine was under scrutiny due to concerns about potential associations with blood clotting disorders, which had also put it on hold in several European countries.
Child Vaccination Laws: State-by-State Differences
You may want to see also
Explore related products
AstraZeneca's COVID-19 vaccine was found to be less safe than Pfizer's
In 2020, top scientific journals published studies declaring COVID-19 vaccines, including Pfizer and AstraZeneca, to be safe and effective. However, recent analyses of data from these studies have revealed that AstraZeneca's COVID-19 vaccine may be less safe than Pfizer's.
Scientists from Children's Health Defense and the Brownstone Institute reanalyzed the data used in earlier studies and found evidence linking both the Pfizer and AstraZeneca vaccines to significant health dangers. Notably, they discovered that the risks for cardiovascular disease and death from the AstraZeneca vaccine were significantly higher than those of the Pfizer vaccine. The AstraZeneca vaccine was also associated with blood clotting disorders, leading to a halt in its rollout in several European countries.
Jablonowski and colleagues performed a safety analysis of the two vaccines using large datasets from the UK and found that the risks for myocarditis and pericarditis associated with the Pfizer vaccines were evident in earlier studies, despite claims of "cardiovascular safety." They also confirmed the higher risks associated with the AstraZeneca vaccine, concluding that the Nature Communications study promoting cardiovascular safety was "biased by design."
The findings highlight the importance of independent research and the need for transparency in medical research to ensure the public's safety and trust in vaccines. As of the latest information, AstraZeneca's COVID-19 vaccine has not been approved by the U.S. Food and Drug Administration (FDA) due to concerns about blood clotting disorders. The company has not yet submitted its vaccine for approval in the United States.
Postal Workers: Vaccination Status and the Law
You may want to see also
Explore related products
AstraZeneca's vaccine has not been approved by the FDA
AstraZeneca's COVID-19 vaccine has not been approved by the FDA for use in the United States. The pharmaceutical company is yet to submit its vaccine for approval. According to the FDA, AstraZeneca has not yet applied for Emergency Use Authorization approval.
AstraZeneca is several weeks away from being able to apply for FDA approval. The FDA requires that at least half of the participants have two months of follow-up, which is what they required for Johnson & Johnson, Pfizer, and Moderna. AstraZeneca needs to gather all the data from the Phase III trial and present it to the FDA.
Experts initially pointed to April as the time when AstraZeneca would be ready to apply for FDA approval. However, the vaccine has been put on hold in many European countries due to concerns about its possible association with blood clotting disorders. The FDA is closely monitoring the situation in Europe and is expected to consider this issue when evaluating AstraZeneca's vaccine for approval.
As of now, there is no clear timeline for when AstraZeneca's vaccine will be approved by the FDA for use in the United States. The company first needs to submit its application for approval, after which the FDA will conduct its review process.
Merck's Mumps Vaccine: Unfair Monopoly?
You may want to see also
Frequently asked questions
No, the AstraZeneca vaccine is not available in the United States.
No, AstraZeneca has not applied for approval in the United States.
The FDA requires that at least half of the participants have two months of follow-up. AstraZeneca needs to collate this data and present it to the FDA.
AstraZeneca is several weeks away from being able to apply for approval. Experts predicted that AstraZeneca would be ready to apply for approval in April.
